Preclinical Evaluation of a Monoclonal Antibody (3C6) Specific for Prostate-Specific Membrane Antigen
Authors:
- 1 January 2009
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Current Radiopharmaceuticals
- Vol. 2 (1) , 9-17
Abstract
Better tumor markers are needed for early diagnosis and staging of prostate cancer, and for monitoring therapeutic response than the currently used prostate specific antigen (PSA). Prostate specific membrane antigen (PSMA) is highly expressed on the surface of prostatic epithelial cells making it a good target for prostate cancer. In this study, mAb 3C6, specific for the extracellular epitope of PSMA, was evaluated both in vitro and in vivo for PSMA-targeting. Immunoreactivity and specificity of mAb 3C6 was evaluated by flow cytometry using prostate cell lines expressing PSMA such as LNCaP and 22Rv1 and a cell line, DU145, that expresses very little PSMA. 3C6 was conjugated with the acyclic CHX-A” DTPA chelate, radiolabeled with 111In, and its in vitro and in vivo properties were assessed. The biodistribution of the radioimmunoconjugate evaluated in athymic mice bearing xenografts of three human prostate carcinoma cell lines shows high uptake after 72 hr in LNCaP tumors (%ID/g 22.93 + 6.32) and 22Rv1 (%ID/g 10.44 + 2.32) in contrast to low uptake by the DU145 tumors (%ID/g 4.27 + 0.37). Planar γ-scintigraphic images obtained for xenografted tumor bearing mice demonstrated targeting for PSMA positive tumors suggesting possible applications in imaging and for targeted radiation therapy.Keywords
This publication has 11 references indexed in Scilit:
- Preparation and Characterization of New Anti-PSMA Monoclonal Antibodies with Potential Clinical UseHybridoma, 2007
- Prostate‐specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray techniqueHistopathology, 2007
- Vascular Targeted Therapy With Anti–Prostate-Specific Membrane Antigen Monoclonal Antibody J591 in Advanced Solid TumorsJournal of Clinical Oncology, 2007
- A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancerThe Prostate, 2006
- Arming antibodies: prospects and challenges for immunoconjugatesNature Biotechnology, 2005
- Clinical Use of Monoclonal Antibody HuJ591 Therapy: Targeting Prostate Specific Membrane AntigenJournal of Urology, 2003
- Targeting Metastatic Prostate Cancer With Radiolabeled Monoclonal Antibody J591 to the Extracellular Domain of Prostate Specific Membrane AntigenJournal of Urology, 2003
- Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): Studies in nude miceThe Prostate, 2003
- In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigenProstate Cancer and Prostatic Diseases, 2002
- PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENTJournal of Biological Chemistry, 1951